News articles about Onconova Therapeutics (NASDAQ:ONTX) have trended positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Onconova Therapeutics earned a coverage optimism score of 0.29 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 47.4865339674639 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Onconova Therapeutics (NASDAQ:ONTX) opened at 1.73 on Friday. Onconova Therapeutics has a 52-week low of $1.50 and a 52-week high of $3.88. The firm has a 50-day moving average price of $1.75 and a 200 day moving average price of $2.19. The stock’s market cap is $17.04 million.
Onconova Therapeutics (NASDAQ:ONTX) last announced its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.43. The firm had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.25 million. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 762.13%. Equities analysts anticipate that Onconova Therapeutics will post ($2.92) earnings per share for the current year.
Several brokerages recently weighed in on ONTX. Maxim Group set a $6.00 price target on Onconova Therapeutics and gave the stock a “buy” rating in a report on Tuesday, June 6th. Dawson James reiterated a “buy” rating on shares of Onconova Therapeutics in a research report on Tuesday, July 25th. Finally, ValuEngine upgraded Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.
About Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Receive News & Ratings for Onconova Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.